Abstract:Background/Aims: Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-ZJU01/ 2013(H7N9) was effective in protecting against highly pathogenic H7N9, we conducted this study. Methods: Groups of mice were immunized twice by intraperitoneal injection with 500 mu l of either split vaccine alone or MF59- adjuvanted vaccine. Serum was collected 2 weeks after the second vaccine booster. The hemagglutinin inhibition test was conducted on vaccine seed and highly pathogenic H7N9 to evaluate the neutralization of highly pathogenic H7N9. We also immunized mice and challenged them with highly pathogenic H7N9. Mice were observed for illness, weight loss, and death at 1 week and 2 weeks post- infection. Then, the mice were sacrificed and lungs were removed. Antibody responses were assessed and pathological changes in the lung tissue were evaluated. Results: The ability of serum to neutralize highly pathogenic H7N9 was reduced. In mice, highly pathogenic H7N9 was more virulent than A/Zhejiang/DTID- ZJU01/2013(H7N9). After challenge with highly pathogenic H7N9, all mice died while mice challenged with A/Zhejiang/DTID- ZJU01/2013(H7N9) all recovered. The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine was able to protect against infection with highly pathogenic H7N9 in mice, with or without MF59. Moreover, H7N9 vaccine adjuvanted with MF59 produced high antibody levels, which lead to better protection. Conclusions: The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine based on A/Zhejiang/DTID- ZJU01/2013( H7N9) is effective in protecting against highly pathogenic H7N9. H7N9 vaccine adjuvanted with MF59 offers better protection against infection with highly pathogenic H7N9. In order to make the H7N9 vaccine applicable to humans, further clinical trials are required to evaluate MF59 adjuvanted vaccine. Meanwhile, the vaccine strain should be updated based on the highly pathogenic H7N9 gene sequence. (C) 2018 The Author(s) Published by S. Karger AG, Basel

Vibrationally resolved carbon core excitations in alkane molecules.

Response by Behme to Letter Regarding Article, "Emergent Carotid Stenting After Thrombectomy in Patients With Tandem Lesions".

Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.

Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles

Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice

Isolation and characterization of genetic variants of Orthohantavirus hantanense from clinical cases of HFRS in Jiangxi Province, China

Epidemic Trend and Molecular Evolution of HV Family in the Main Hantavirus Epidemic Areas From 2004 to 2016, in P.R. China

Diversity and Genetic Characterization of Orthohantavirus from Small Mammals and Humans during 2012-2022 in Hubei Province, Central China

Preclinical Evaluation of the Safety and Pathogenicity of a Live Attenuated Recombinant Influenza A/H7N9 Seed Strain and Corresponding MF59-adjuvanted Split Vaccine

Construction and Immunological Characterization of Cd40l or Gm-Csf Incorporated Hantaan Virus Like Particle

Study on the Recombinant Expression of Hantaan Virus Protein N and the Establishment and Application of Rnp-Igm Direct Capture ELISA

HTNV infection of CD8+ T cells is associated with disease progression in HFRS patients

HTNV Sensitizes Host Toward TRAIL-Mediated Apoptosis-A Pivotal Anti-hantaviral Role of TRAIL.

Immunogenicity of a Multi-Epitope DNA Vaccine Against Hantavirus.

© 2012 Landes Bioscience. Do not distribute. Immunogenicity of a multi-epitope DNA vaccine against hantavirus

Genetic Evolution Analysis and Host Characteristics of Hantavirus in Yunnan Province, China

Development of Small-Molecule Inhibitors Against Hantaviruses.

Induction Of Specific Humoral And Cellular Immune Responses In A Mouse Model Following Gene Fusion Of Hsp70c And Hantaan Virus Gn And S0.7 In An Adenoviral Vector

Infection and Pathogenesis of Huaiyangshan Virus (A Novel Tick-Borne Bunyavirus) in Laboratory Rodents

Investigation on the Natural Infectious Status of Hantaviruses among Small Mammals in Longquan City, Zhejiang Province